FMR CORP 13D and 13G filings for Fulcrum Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-10-07 11:37 am Sale |
2024-10-04 | 13G | Fulcrum Therapeutics, Inc. FULC |
FMR CORP | 1,724,014 2.762% |
-3,960,601 (-69.67%) |
Filing |
| 2024-02-09 09:03 am Purchase |
2024-02-08 | 13G | Fulcrum Therapeutics, Inc. FULC |
FMR CORP | 5,684,615 9.195% |
450,890 (+8.62%) |
Filing |
| 2023-02-09 10:59 am Sale |
2023-02-09 | 13G | Fulcrum Therapeutics, Inc. FULC |
FMR CORP | 5,233,725 10.054% |
-848,592 (-13.95%) |
Filing |
| 2022-02-09 09:19 am Purchase |
2022-02-08 | 13G | Fulcrum Therapeutics, Inc. FULC |
FMR CORP | 6,082,317 14.999% |
37,554 (+0.62%) |
Filing |
| 2021-09-10 09:33 am Purchase |
2021-09-09 | 13G | Fulcrum Therapeutics, Inc. FULC |
FMR CORP | 6,044,763 14.999% |
4,295,027 (+245.47%) |
Filing |
| 2021-02-08 10:23 am Purchase |
2021-02-05 | 13G | Fulcrum Therapeutics, Inc. FULC |
FMR CORP | 1,749,736 6.371% |
48,985 (+2.88%) |
Filing |